What Are Triglycerides?

What are triglycerides? Triglycerides are the most abundant type of fat (lipid) in the human body and bloodstream. Chemically, a triglyceride consists of three fatty acid chains bonded to a glycerol molecule — hence the name "tri-glyceride." What is triglycerides in practical terms? They are the body's primary form of stored energy — the molecular currency of fat storage.

Triglycerides enter your blood from two sources. The first is dietary absorption: when you eat fat, it is digested and packaged into lipoprotein particles called chylomicrons, which deliver triglycerides to tissues throughout the body. The second — and for metabolic health, far more consequential — source is hepatic production: the liver manufactures triglycerides from excess carbohydrates through a process called de novo lipogenesis (DNL). This is the pathway by which surplus sugar is converted into fat.

Under normal metabolic conditions, triglycerides serve essential functions: they are the body's most efficient energy storage molecule (9 calories per gram versus 4 for carbohydrates), they insulate organs, and they transport fat-soluble vitamins. The problem arises when triglyceride production exceeds the body's ability to clear them — leading to elevated blood triglycerides, fat accumulation in the liver, and a cascade of metabolic consequences including cardiovascular disease, insulin resistance, and fatty liver disease.

TRIGLYCERIDE LEVEL REFERENCE RANGES

What Level of Triglycerides Is Dangerous?

What level of triglycerides is dangerous? While any level above 150 mg/dL signals metabolic dysfunction, the clinical danger thresholds are stratified by risk:

High triglycerides (200–499 mg/dL) significantly increase cardiovascular risk. At these levels, the characteristic "atherogenic dyslipidemia" pattern typically emerges: high triglycerides + low HDL + small dense LDL particles. This lipid triad is a hallmark of metabolic syndrome and is more predictive of heart attack and stroke risk than LDL cholesterol alone. High triglycerides at this level also indicate substantial hepatic de novo lipogenesis activity — meaning the liver is actively converting sugar to fat.

Very high triglycerides (≥500 mg/dL) are medically dangerous because they carry a significant risk of acute pancreatitis — a painful and potentially life-threatening inflammation of the pancreas caused by triglyceride-rich lipoprotein particles damaging pancreatic capillaries. This is a medical emergency requiring immediate treatment.

However, many metabolic health researchers argue that the standard "normal" threshold of 150 mg/dL is too permissive. Emerging evidence suggests that optimal triglycerides are below 100 mg/dL, and that levels between 100–149 mg/dL — while technically "normal" — already indicate early metabolic dysfunction, particularly when combined with insulin resistance, low HDL cholesterol, or elevated fasting insulin. The ratio of triglycerides to HDL (TG/HDL ratio) is increasingly used as a surrogate marker for insulin resistance — a ratio above 2.0 suggests significant metabolic dysfunction even when individual values appear "normal."

What Causes High Triglycerides?

Understanding what causes high triglycerides requires distinguishing between the dietary, metabolic, and hormonal drivers that elevate blood lipids. While high triglycerides are commonly attributed to "eating too much fat," the reality is that the liver's production of triglycerides from carbohydrates — particularly fructose — is the primary driver of elevated blood triglycerides in most people.

PRIMARY CAUSES OF HIGH TRIGLYCERIDES

How Fructose Drives Triglyceride Elevation: The Metabolic Pathway

The connection between fructose and triglycerides is one of the most important and well-documented relationships in metabolic biochemistry. Fructose is uniquely lipogenic — meaning it preferentially drives fat synthesis rather than energy production — and the triglycerides produced through this pathway are the central link between dietary sugar and cardiovascular disease.

The mechanism operates through the following pathway:

• Unregulated fructokinase metabolism: Fructokinase (KHK-C) phosphorylates fructose without feedback inhibition — processing it as fast as it arrives regardless of the cell's energy status. This depletes ATP, generates uric acid, and produces large quantities of acetyl-CoA — the building block for fatty acid synthesis.
• De novo lipogenesis activation: The excess acetyl-CoA is converted to fatty acids by acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS). These fatty acids are assembled into triglycerides. Fructose also activates SREBP-1c and ChREBP — transcription factors that upregulate all DNL enzymes, increasing the liver's capacity to manufacture fat. Understanding why fructose has become the primary driver of the silent fatty liver epidemic begins with this DNL-triglyceride connection.
• VLDL export → elevated blood triglycerides: The newly synthesised triglycerides are packaged with ApoB-100 into VLDL (very low-density lipoprotein) particles and exported from the liver into the bloodstream. This is the direct mechanism by which fructose consumption raises blood triglyceride levels — and why fructose reduction is the single most effective dietary strategy for lowering triglycerides.
• AMPK suppression removes the brake: Under normal conditions, AMPK activation would inhibit ACC (the rate-limiting DNL enzyme) and slow triglyceride production. But fructose metabolism actively suppresses AMPK — removing the metabolic brake on fat synthesis and allowing DNL to proceed at maximum capacity.

Controlled overfeeding studies demonstrate the potency of this pathway: fructose increases hepatic de novo lipogenesis rates 3–5 times more than equivalent glucose loads, with 25–30% of ingested fructose converted to fat versus less than 1% for glucose (Stanhope et al., 2009; Schwarz et al., 2015).

The Endogenous Triglyceride Engine: When Your Body Makes Its Own Fructose

One of the most clinically important discoveries in triglyceride research is that high blood glucose itself can generate fructose inside the body — which then drives de novo lipogenesis and raises triglycerides even in someone consuming no dietary fructose.

When blood glucose is chronically elevated, the polyol pathway activates: aldose reductase converts glucose to sorbitol, which is then converted to endogenous fructose. This internally produced fructose is metabolised by fructokinase through the same unregulated pathway as dietary fructose — generating uric acid, depleting ATP, driving DNL, and producing triglycerides.

This creates a vicious cycle: high glucose → endogenous fructose → de novo lipogenesis → more triglycerides → more liver fat → more insulin resistance → higher glucose → more endogenous fructose. Breaking this cycle requires addressing both dietary fructose intake and the underlying insulin resistance that keeps blood glucose — and therefore endogenous fructose production — elevated. This hidden mechanism explains why some patients with "clean" diets still present with stubbornly elevated triglycerides and progressive fatty liver disease.

Health Consequences of High Triglycerides

High triglycerides are not merely a number on a lab report — they indicate active, ongoing metabolic damage and independently predict serious health outcomes:

HEALTH CONSEQUENCES OF ELEVATED TRIGLYCERIDES

Why "Low-Fat" Diets Can Actually Raise Triglycerides

One of the most counterintuitive facts about triglyceride metabolism is that dietary fat is not the primary driver of elevated blood triglycerides — dietary carbohydrates are. This paradox has led millions of people to follow low-fat, high-carbohydrate diets in an attempt to lower triglycerides, only to see their levels rise.

The explanation lies in de novo lipogenesis. When dietary fat is replaced with carbohydrates (particularly refined carbohydrates and sugars), the liver receives more substrate for DNL. Excess glucose and fructose are converted to fatty acids, assembled into triglycerides, and exported as VLDL — raising blood triglyceride levels. A meta-analysis by Schwarz et al. (2017) demonstrated that reducing dietary fructose in children with obesity decreased hepatic DNL by 56% and blood triglycerides significantly — without changing total calorie intake.

This is why the most effective dietary approach for lowering triglycerides is not fat restriction but fructose and refined carbohydrate reduction. Understanding how blood sugar spikes fuel cravings and keep the DNL cycle active reveals why simple calorie counting misses the metabolic root of the problem. For a comprehensive dietary approach, our guide on mastering a low-glycemic lifestyle provides actionable strategies.

How to Lower Triglycerides Naturally

Understanding how to lower triglycerides naturally requires targeting the metabolic pathways that produce them — rather than simply reducing dietary fat. The most effective strategies address fructose metabolism, de novo lipogenesis, insulin signalling, and the body's capacity to clear triglycerides from the blood.

EVIDENCE-BASED STRATEGIES TO LOWER TRIGLYCERIDES

Supplements That Lower Triglycerides at the Metabolic Root

While lifestyle and dietary changes form the foundation of triglyceride management, several natural compounds directly target the metabolic pathways responsible for triglyceride overproduction:

• Berberine: A plant alkaloid that activates AMPK — the master metabolic switch that inhibits acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in de novo lipogenesis. By turning on AMPK, berberine effectively applies the brakes to hepatic triglyceride production. Clinical meta-analyses show berberine reduces blood triglycerides by 35–45 mg/dL on average (Lan et al., 2015). Berberine also improves insulin sensitivity, reducing the hyperinsulinemia that drives SREBP-1c-mediated DNL upregulation.
• Luteolin: A polyphenol that inhibits fructokinase — the enzyme that initiates the entire fructose → DNL → triglyceride cascade. By blocking fructokinase, luteolin reduces fructose-driven ATP depletion, uric acid generation, and the substrate flow into de novo lipogenesis. Luteolin also suppresses SREBP-1c expression and has direct anti-inflammatory properties. Explore luteolin's role as a natural warrior against the metabolic syndrome cascade.
• Tart cherry extract: Rich in anthocyanins with demonstrated uric acid-lowering and anti-inflammatory properties. Tart cherry extract addresses the downstream metabolic damage from fructose-driven triglyceride production — reducing uric acid (which compounds oxidative stress and inflammation) and supporting healthy sleep (via natural melatonin content), which itself improves triglyceride metabolism.

These compounds address complementary points along the triglyceride production pathway: luteolin blocks the upstream fructokinase enzyme, berberine activates the central AMPK brake, and tart cherry extract reduces downstream uric acid damage — the comprehensive metabolic strategy behind SugarShield.

Triglycerides and Women: Gender-Specific Considerations

Women face unique triglyceride challenges tied to hormonal changes across the lifespan:

• PCOS and triglycerides: Women with polycystic ovary syndrome frequently present with elevated triglycerides as part of the metabolic profile — driven by insulin resistance and hyperinsulinemia that activate hepatic de novo lipogenesis.
• Perimenopause and menopause: Oestrogen decline during menopause reduces lipoprotein lipase activity and shifts lipid metabolism, causing triglycerides to rise significantly — often by 16–20% in the years surrounding menopause. This hormonal shift increases cardiovascular risk and is compounded by the metabolic changes described in our article on the relationship between weight gain and blood sugar dysregulation.
• Oral contraceptives and HRT: Oestrogen-containing medications can elevate triglycerides in susceptible women — particularly those with underlying insulin resistance or genetic predisposition.

For women experiencing these hormonal transitions, addressing the metabolic root of triglyceride elevation — fructose metabolism, insulin resistance, and de novo lipogenesis — is particularly important, as hormonal changes amplify the impact of these metabolic drivers.

How to Monitor Your Triglyceride Levels

Triglycerides are measured through a standard lipid panel blood test — the same test that measures total cholesterol, LDL, and HDL. For accurate results, the test requires a 9–12 hour fast (non-fasting triglycerides are typically higher and less clinically useful for comparison).

Beyond the absolute triglyceride number, pay attention to these key ratios and patterns:

• TG/HDL ratio: Divide your triglycerides by your HDL cholesterol. A ratio below 2.0 is optimal; above 2.0 suggests insulin resistance; above 3.5 indicates significant metabolic dysfunction. This ratio is a powerful surrogate marker for small dense LDL particles — the most atherogenic subtype — without needing advanced lipid testing.
• The metabolic syndrome pattern: Triglycerides ≥150 mg/dL + HDL <40 mg/dL (men) or <50 mg/dL (women) + waist circumference >40 inches (men) or >35 inches (women) + fasting glucose ≥100 mg/dL + blood pressure ≥130/85. Three or more of these five criteria define metabolic syndrome.
• Trending over time: A single triglyceride measurement is a snapshot. Track trends over 3–6 month intervals to assess whether dietary and lifestyle interventions are working. Rising triglycerides — even within the "normal" range — warrant metabolic investigation.

For a comprehensive metabolic assessment, request fasting insulin alongside the standard lipid panel. The combination of fasting triglycerides, fasting insulin, and fasting glucose provides the most complete picture of metabolic health available through routine blood work. Learn more about building your metabolism's resilience in our guide on how to sugar-proof your metabolism.

When to see a doctor: If your triglycerides are above 200 mg/dL, or above 150 mg/dL combined with low HDL, elevated fasting glucose, or abdominal obesity — consult a healthcare provider for comprehensive metabolic evaluation. Triglycerides above 500 mg/dL require urgent medical attention due to pancreatitis risk. Request a full lipid panel with fasting insulin, HbA1c, uric acid, and liver function tests for a complete metabolic picture. Do not stop or adjust any prescribed lipid-lowering medication without medical guidance. This content is for informational purposes only and does not constitute medical advice.

References

• Banks, W. A., Coon, A. B., Robinson, S. M., et al. (2004). Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes, 53(5), 1253–1260.
• Grundy, S. M. (2016). Metabolic syndrome update. Trends in Cardiovascular Medicine, 26(4), 364–373.
• Hannou, S. A., Haslam, D. E., McKeown, N. M., & Herman, M. A. (2018). Fructose metabolism and metabolic disease. Journal of Clinical Investigation, 128(2), 545–555.
• Lan, J., Zhao, Y., Dong, F., et al. (2015). Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology, 161, 69–81.
• Lanaspa, M. A., Ishimoto, T., Li, N., et al. (2013). Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nature Communications, 4, 2434.
• Schwarz, J. M., Noworolski, S. M., Erkin-Cakmak, A., et al. (2017). Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology, 153(3), 743–752.
• Stanhope, K. L., Schwarz, J. M., Keim, N. L., et al. (2009). Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation, 119(5), 1322–1334.
• Tappy, L., & Lê, K. A. (2010). Metabolic effects of fructose and the worldwide increase in obesity. Physiological Reviews, 90(1), 23–46.